Dipeptidyl peptidase IV (DPP4)-deficiency attenuates diet-induced obesity in rats: Possible implications for the hypothalamic neuropeptidergic system

Behavioural Brain Research

Volumn 216, Issue 2, 2011, Pages 712-718

  Stephan, Michael ^a   Radicke, Anna ^a   Leutloff, Sandra ^a   Schmiedl, Andreas ^a   Pabst, Reinhard ^a   von Hörsten, Stephan ^b   Dettmer, Sabine ^a   Lotz, Joachim ^a   Nave, Heike ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

CD26; DPP4; Incretins; Leptin; NPY; Obesity; PYY; Rats

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; LEPTIN RECEPTOR; NUCLEAR FACTOR Y;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY FAT DISTRIBUTION; CONTROLLED STUDY; DIPEPTIDYL PEPTIDASE IV DEFICIENCY; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME DEFICIENCY; HOMEOSTASIS; HYPOTHALAMUS; IMMUNOREACTIVITY; LIPID ANALYSIS; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PEPTIDERGIC NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RAT; WEIGHT REDUCTION;

ANIMALS; APPETITE REGULATION; DIETARY FATS; DIPEPTIDYL PEPTIDASE 4; DISEASE MODELS, ANIMAL; ENERGY INTAKE; GENE KNOCKOUT TECHNIQUES; INTRA-ABDOMINAL FAT; MALE; NEUROPEPTIDE Y; OBESITY; RATS; RATS, INBRED STRAINS; RECEPTORS, NEUROPEPTIDE Y; WEIGHT GAIN;

EID: 78149497859     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.09.024     Document Type: Article

References (54)

1. Hainer V., Toplak H., Mitrakou A. Treatment modalities of obesity: what fits whom?. Diabetes Care 2008, 31(Suppl. 2):S269-S277.
2. Muller-Riemenschneider F., Reinhold T., Berghofer A., Willich S.N. Health-economic burden of obesity in Europe. Eur J Epidemiol 2008, 23(8):499-509.
3. Ogden C.L., Yanovski S.Z., Carroll M.D., Flegal K.M. The epidemiology of obesity. Gastroenterology 2007, 132(6):2087-2102.
4. Smith P.M., Ferguson A.V. Neurophysiology of hunger and satiety. Dev Disabil Res Rev 2008, 14(2):96-104.
5. Valassi E., Scacchi M., Cavagnini F. Neuroendocrine control of food intake. Nutr Metab Cardiovasc Dis 2008, 18(2):158-168.
6. Friedman J.M., Halaas J.L. Leptin and the regulation of body weight in mammals. Nature 1998, 395(6704):763-770.
7. Ahima R.S., Flier J.S. Leptin Annu Rev Physiol 2000, 62:413-437.
8. Margetic S., Gazzola C., Pegg G.G., Hill R.A. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 2002, 26(11):1407-1433.
9. Brabant G., Nave H., Mayr B., Behrend M., van Harmelen V., Arner P. Secretion of free and protein-bound leptin from subcutaneous adipose tissue of lean and obese women. J Clin Endocrinol Metab 2002, 87(8):3966-3970.
10. Vaisse C., Halaas J.L., Horvath C.M., Darnell J.E., Stoffel M., Friedman J.M. Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nat Genet 1996, 14(1):95-97.
11. Morrison C.D., Morton G.J., Niswender K.D., Gelling R.W., Schwartz M.W. Leptin inhibits hypothalamic Npy and Agrp gene expression via a mechanism that requires phosphatidylinositol 3-OH-kinase signaling. Am J Physiol Endocrinol Metab 2005, 289(6):E1051-E1057.
12. Veldhorst M., Smeets A., Soenen S., Hochstenbach-Waelen A., Hursel R., Diepvens K., et al. Protein-induced satiety: effects and mechanisms of different proteins. Physiol Behav 2008, 94(2):300-307.
13. Aronne L.J., Thornton-Jones Z.D. New targets for obesity pharmacotherapy. Clin Pharmacol Ther 2007, 81(5):748-752.
14. Field B.C., Wren A.M., Cooke D., Bloom S.R. Gut hormones as potential new targets for appetite regulation and the treatment of obesity. Drugs 2008, 68(2):147-163.
15. Mentlein R., Dahms P., Grandt D., Kruger R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 1993, 49(2):133-144.
16. Mentlein R., Gallwitz B., Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993, 214(3):829-835.
17. De Meester I., Korom S., Van Damme J., Scharpe S. CD26, let it cut or cut it down. Immunol Today 1999, 20(8):367-375.
18. Gallwitz B., Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc) 2007, 43(1):13-25.
19. Nave H., Mueller G., Siegmund B., Jacobs R., Stroh T., Schueler U., et al. Resistance of Janus kinase-2 dependent leptin signaling in natural killer (NK) cells: a novel mechanism of NK cell dysfunction in diet-induced obesity. Endocrinology 2008, 149(7):3370-3378.
20. Frerker N., Raber K., Bode F., Skripuletz T., Nave H., Klemann C., et al. Phenotyping of congenic dipeptidyl peptidase 4 (DP4) deficient Dark Agouti (DA) rats suggests involvement of DP4 in neuro-, endocrine, and immune functions. Clin Chem Lab Med 2009, 47(3):275-287.
21. Rehbinder C, Baneux P, Forbes D, van Herck H, Nicklas W, Rugaya Z, et al. FELASA recommendations for the health monitoring of mouse, rat, hamster, gerbil, guinea pig and rabbit experimental units. Report of the Federation of European Laboratory Animal Science Associations (FELASA) Working Group on Animal Health accepted by the FELASA Board of Management, November 1995. Lab Anim 1996; 30(3): 193-208.
22. Bode F.J., Stephan M., Suhling H., Pabst R., Straub R.H., Raber K.A., et al. Sex differences in a transgenic rat model of Huntington's disease: decreased 17β-estradiol levels correlate with reduced numbers of DARPP32+ neurons in males. Hum Mol Genet 2008, 17(17):2595-2609.
23. Howard C.V., Reed G.M. Unbiased stereology. Three-dimensional measurement in microscopy 2005, Garland Science/Bios Scientific Publishers. 2nd ed.
24. Muller A.E., Cruz-Orive L.M., Gehr P., Weibel E.R. Comparison of two subsampling methods for electron microscopic morphometry. J Microsc 1981, 123(Pt 1):35-49.
25. Sterio D.C. The unbiased estimation of number and sizes of arbitrary particles using the disector. J Microsc 1984, 134(Pt 2):127-136.
26. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008(2): CD006739.
27. Lamont B.J., Drucker D.J. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes 2008, 57(1):190-198.
28. Gutzwiller J.P., Goke B., Drewe J., Hildebrand P., Ketterer S., Handschin D., et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999, 44(1):81-86.
29. Considine R.V., Sinha M.K., Heiman M.L., Kriauciunas A., Stephens T.W., Nyce M.R., et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996, 334(5):292-295.
30. Maffei M., Halaas J., Ravussin E., Pratley R.E., Lee G.H., Zhang Y., et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995, 1(11):1155-1161.
31. Elmquist J.K., Bjorbaek C., Ahima R.S., Flier J.S., Saper C.B. Distributions of leptin receptor mRNA isoforms in the rat brain. J Comp Neurol 1998, 395(4):535-547.
32. Banks W.A., Farrell C.L. Impaired transport of leptin across the blood-brain barrier in obesity is acquired and reversible. Am J Physiol Endocrinol Metab 2003, 285(1):E10-E15.
33. Enriori P.J., Evans A.E., Sinnayah P., Cowley M.A. Leptin resistance and obesity. Obesity (Silver Spring) 2006, 14(Suppl. 5):254S-258S.
34. Hindlet P., Bado A., Kamenicky P., Delomenie C., Bourasset F., Nazaret C., et al. Reduced intestinal absorption of dipeptides via PepT1 in mice with diet-induced obesity is associated with leptin receptor down-regulation. J Biol Chem 2009, 284(11):6801-6808.
35. Moran T.H., Dailey M.J. Minireview: gut peptides: targets for antiobesity drug development?. Endocrinology 2009, 150(6):2526-2530.
36. Murphy K.G., Dhillo W.S., Bloom S.R. Gut peptides in the regulation of food intake and energy homeostasis. Endocr Rev 2006, 27(7):719-727.
37. Tschöp M., Castaneda T.R., Joost H.G., Thone-Reineke C., Ortmann S., Klaus S., et al. Physiology: does gut hormone PYY3-36 decrease food intake in rodents?. Nature 2004, 430(6996). 1 p following 165; discussion 2 p following.
38. Batterham R.L., Cohen M.A., Ellis S.M., Le Roux C.W., Withers D.J., Frost G.S., et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003, 349(10):941-948.
39. Abbott C.R., Small C.J., Kennedy A.R., Neary N.M., Sajedi A., Ghatei M.A., et al. Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake. Brain Res 2005, 1043(1-2):139-144.
40. Batterham R.L., Cowley M.A., Small C.J., Herzog H., Cohen M.A., Dakin C.L., et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002, 418(6898):650-654.
41. Larhammar D., Salaneck E. Molecular evolution of NPY receptor subtypes. Neuropeptides 2004, 38(4):141-151.
42. Dailey M.J., Bartness T.J. Appetitive and consummatory ingestive behaviors stimulated by PVH and perifornical area NPY injections. Am J Physiol Regul Integr Comp Physiol 2009, 296(4):R877-R892.
43. Erondu N., Gantz I., Musser B., Suryawanshi S., Mallick M., Addy C., et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 2006, 4(4):275-282.
44. Hanson E.S., Dallman M.F., Neuropeptide Y (NPY) may integrate responses of hypothalamic feeding systems and the hypothalamo-pituitary-adrenal axis. J Neuroendocrinol 1995, 7(4):273-279.
45. Buchenauer T., Behrendt P., Bode F.J., Horn R., Brabant G., Stephan M., et al. Diet-induced obesity alters behavior as well as serum levels of corticosterone in F344 rats. Physiol Behav 2009, 98(5):563-569.
46. Karl T., Hoffmann T., Pabst R., von Horsten S. Behavioral effects of neuropeptide Y in F344 rat substrains with a reduced dipeptidyl-peptidase IV activity. Pharmacol Biochem Behav 2003, 75(4):869-879.
47. Karl T., Hoffmann T., Pabst R., von Horsten S. Extreme reduction of dipeptidyl peptidase IV activity in F344 rat substrains is associated with various behavioral differences. Physiol Behav 2003, 80(1):123-134.
48. Ramadori G., Fujikawa T., Fukuda M., Anderson J., Morgan D.A., Mostoslavsky R., et al. SIRT1 deacetylase in POMC neurons is required for homeostatic defenses against diet-induced obesity. Cell Metab 2010, 12(1):78-87.
49. Zhang Y., Rodrigues E., Gao Y.X., King M., Cheng K.Y., Erdos B., et al. Pro-opiomelanocortin gene transfer to the nucleus of the solitary track but not arcuate nucleus ameliorates chronic diet-induced obesity. Neuroscience 2010, 169(4):1662-1671.
50. de Backer M.W., la Fleur S.E., Brans M.A., van Rozen A.J., Luijendijk M.C., Merkestein M., et al. Melanocortin receptor-mediated effects on obesity are distributed over specific hypothalamic regions. Int J Obes (Lond) 2010.
51. Rebuffe-Scrive M., Anderson B., Olbe L., Bjorntorp P. Metabolism of adipose tissue in intraabdominal depots in severely obese men and women. Metabolism 1990, 39(10):1021-1025.
52. Rebuffe-Scrive M., Andersson B., Olbe L., Bjorntorp P. Metabolism of adipose tissue in intraabdominal depots of nonobese men and women. Metabolism 1989, 38(5):453-458.
53. Liu K.H., Chan Y.L., Chan J.C., Chan W.B., Kong W.L. Mesenteric fat thickness as an independent determinant of fatty liver. Int J Obes (Lond) 2006, 30(5):787-793.
54. Liu K.H., Chan Y.L., Chan W.B., Chan J.C., Chu C.W. Mesenteric fat thickness is an independent determinant of metabolic syndrome and identifies subjects with increased carotid intima-media thickness. Diabetes Care 2006, 29(2):379-384.